Restricted accessReview articleFirst published online 2026-1
Incidence of dementia in patients with type 2 diabetes using SGLT2 inhibitors versus GLP-1 receptor agonists or DPP-4 inhibitors: A systematic review and meta-analysis of cohort studies
Individuals with type 2 diabetes mellitus (T2DM) have a higher incidence of dementia than those without the disease, possibly due to overlapping pathophysiological mechanisms. While glycemic control is essential to reduce dementia risk, recent studies suggest that newer antidiabetic agents, SGLT2i, GLP-1 RA, and DPP-4i, may offer neuroprotective effects.
Objective
To investigate the incidence of dementia in T2DM patients treated with SGLT2i compared to GLP-1 RA or DPP-4i.
Methods
A systematic search of PubMed, Embase, and Cochrane databases was conducted for cohort studies published up to June 2025 that assessed dementia incidence in T2DM patients using SGLT2i versus DPP-4i or GLP-1 RA. Risk ratios (RRs) were calculated using the Mantel-Haenszel random-effects model, with variance estimated via restricted maximum likelihood in R version 4.3.0.
Results
Ten studies met inclusion criteria. Four compared SGLT2i with GLP-1 RA, and seven with DPP-4i; one study contributed to both comparisons. The pooled RR for dementia in SGLT2i versus GLP-1 RA users was 0.91 (95% CI: 0.73–1.12; p < 0.003; I² = 78.7%). When comparing SGLT2i to DPP-4i, the RR was 0.39 (95% CI: 0.28–0.56; p < 0.00001; I² = 96.4%).
Conclusions
Use of SGLT2i was associated with a lower risk of dementia compared to DPP-4i, with no significant difference observed when compared to GLP-1 RA.
ExaltoLGBiesselsGJKarterAJ, et al.Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study. Lancet Diabetes Endocrinol2013; 1: 183–190.
2.
GudalaKBansalDSchifanoF, et al.Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J Diabetes Investig2013; 4: 640–650.
3.
ChatterjeeSPetersSAEWoodwardM, et al.Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care2016; 39: 300–307.
4.
BiesselsGJDespaF. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol2018; 14: 591–604.
5.
TeixeiraLCRPereiraJDMamedeI, et al.Common miRNAs, genes, and regulatory pathways in Alzheimer’s disease and type 2 diabetes mellitus: an integrative analysis of systematic reviews, bioinformatics and data mining. J Neurochem2025; 169: e70196.
6.
CaramelliPMarinhoVLaksJ, et al.Tratamento da demência: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. Dement Neuropsychol2022; 16: 88–100.
7.
American Diabetes Association Professional Practice Committee, ElSayedNAMcCoyRG, et al.4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes—2025. Diabetes Care2025; 48: S59–S85.
8.
ArnoldSEArvanitakisZMacauley-RambachSL, et al.Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol2018; 14: 168–181.
9.
PawlosABroncelMWoźniakE, et al.Neuroprotective effect of SGLT2 inhibitors. Molecules2021; 26: 7213.
10.
JiangXLiJYaoX, et al.Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer’s disease: a narrative review. Front Pharmacol2024; 15: 1361651.
11.
DuHMengXYaoY, et al.The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease. Front Endocrinol2022; 13: 1033479.
12.
TangHShaoHShaabanCE, et al.Newer glucose-lowering drugs and risk of dementia: a systematic review and meta-analysis of observational studies. J Am Geriatr Soc2023; 71: 2096–2106.
13.
YounYJKimSJeongH-J, et al.Sodium-glucose cotransporter-2 inhibitors and their potential role in dementia onset and cognitive function in patients with diabetes mellitus: a systematic review and meta-analysis. Front Neuroendocrinol2024; 73: 101131.
14.
PanJYangHLuJ, et al.The impact of SGLT2 inhibitors on dementia onset in patients with type 2 diabetes: a meta-analysis of cohort studies. Neuroendocrinology2025; 115: 351–359.
15.
HigginsJThomasJChandlerJ, et al.Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024), www.cochrane.org/handbook (2024).
16.
PageMJMcKenzieJEBossuytPM, et al.A declaração PRISMA 2020: diretriz atualizada para relatar revisões sistemáticas. Rev Panam Salud Pública2022; 46: 1.
17.
MantelNHaenszelW. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst1959; 22: 719–748.
18.
DeeksJHigginsJAltmanD, et al.Chapter 10: Analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions. Cochrane, https://www.cochrane.org/handbook (2024).
19.
SchwarzerGCarpenterJRRückerG. Meta-Analysis with R. Cham: Springer International Publishing, 2015.
20.
CohenALevineSZVainsteinG, et al.New-generation antidiabetic medications and dementia risk in older adults with type 2 diabetes: a retrospective cohort study. J Prev Alzheimers Dis2025; 12: 100199.
21.
HongBBeaSKoHY, et al.Sodium–glucose cotransporter-2 inhibitors, dulaglutide, and risk for dementia: a population-based cohort study. Ann Intern Med2024; 177: 1319–1329.
22.
SunMWangXLuZ, et al.Comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in preventing Alzheimer’s disease, vascular dementia, and other dementia types among patients with type 2 diabetes. Diabetes Metab2025; 51: 101623.
23.
TangHDonahooWTSvenssonM, et al.Heterogeneous treatment effects of sodium-glucose cotransporter 2 inhibitors on risk of dementia in people with type 2 diabetes: a population-based cohort study. Alzheimers Dement2024; 20: 5528–5539.
24.
AbdullahZCuiYPlattRW, et al.Association between use of sodium-glucose co-transporter-2 inhibitor and the risk of incident dementia: a population-based cohort study. BMJ Open Diabetes Res Care2025; 13: e004541.
25.
HongBLeeHChoiA, et al.Sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase IV inhibitors and risk of dementia among patients with type 2 diabetes and comorbid mental disorders: a population-based cohort study. Diabetes Metab2024; 50: 101581.
26.
LiuT-HLinY-MYuT, et al.Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a five-year retrospective cohort analysis of 160,752 patients. Diabetes Res Clin Pract2025; 224: 112197.
27.
MuiJVZhouJLeeS, et al.Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. Dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: a propensity score-matched population-based study with competing risk analysis. Front Cardiovasc Med2021; 8: 747620.
28.
WuC-YIskanderCWangC, et al.Association of sodium–glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study. Diabetes Care2023; 46: 297–304.
29.
ZhuoLZhangBYinY, et al.Use of sodium-glucose cotransporter-2 inhibitors and risk of dementia: a population-based cohort study. Diabetes Obes Metab2025; 27: 2430–2441.
30.
TaharaATakasuTYokonoM, et al.Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J Pharmacol Sci2016; 130: 159–169.
31.
KoepsellH. Glucose transporters in brain in health and disease. Pflüg Arch2020; 472: 1299–1343.
32.
ChibaYSugiyamaYNishiN, et al.Sodium/glucose cotransporter 2 is expressed in choroid plexus epithelial cells and ependymal cells in human and mouse brains. Neuropathology2020; 40: 482–491.
33.
LiuGQiuYYouN, et al.Pre-ischaemic empagliflozin treatment attenuates blood–brain barrier disruption via β-catenin mediated protection of cerebral endothelial cells. Cardiovasc Res2025; 121: 788–802.
34.
RizviSShakilSBiswasD, et al.Invokana (canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer’s disease- diabetes type 2 linkage via an enzoinformatics study. CNS Neurol Disord Drug Targets2014; 13: 447–451.
35.
LinBKoibuchiNHasegawaY, et al.Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol2014; 13: 148.
36.
BosDVernooijMWDe BruijnRFAG, et al.Atherosclerotic calcification is related to a higher risk of dementia and cognitive decline. Alzheimers Dement2015; 11: 639.
37.
WingoAPFanWDuongDM, et al.Shared proteomic effects of cerebral atherosclerosis and Alzheimer’s disease on the human brain. Nat Neurosci2020; 23: 696–700.
38.
LiuZMaXIlyasI, et al.Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics. Theranostics2021; 11: 4502–4515.
39.
ZalbaG. Oxidative stress in vascular pathophysiology: still much to learn. Antioxidants2021; 10: 673.
40.
HuangW-JZhangXChenW-W. Role of oxidative stress in Alzheimer’s disease. Biomed Rep2016; 4: 519–522.
41.
YaribeygiHAtkinSLButlerAE, et al.Sodium–glucose cotransporter inhibitors and oxidative stress: an update. J Cell Physiol2019; 234: 3231–3237.
42.
Sa-nguanmooPTanajakPKerdphooS, et al.SGLT2-inhibitor And DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol Appl Pharmacol2017; 333: 43–50.
43.
UddinMRahmanMKabirM, et al.Multifarious roles of mTOR signaling in cognitive aging and cerebrovascular dysfunction of Alzheimer’s disease. IUBMB Life2020; 72: 1843–1855.
44.
StanciuGDRusuRNBildV, et al.Systemic actions of SGLT2 inhibition on chronic mTOR activation as a shared pathogenic mechanism between Alzheimer’s disease and diabetes. Biomedicines2021; 9: 576.
45.
ChenS-DChuangY-CLinT-K, et al.Alternative role of glucagon-like peptide-1 receptor agonists in neurodegenerative diseases. Eur J Pharmacol2023; 938: 175439.
46.
Diz-ChavesYMastoorZSpuchC, et al.Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases. Int J Mol Sci2022; 23: 9583.
47.
AuHCTLamPHLimPK, et al.Role of glucagon-like peptide-1 on amyloid, tau, and α-synuclein: target engagement and rationale for the development in neurodegenerative disorders. Neurosci Biobehav Rev2025; 173: 106159.
48.
BhallaSMehanSKhanA, et al.Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions. Neurosci Biobehav Rev2022; 142: 104896.
49.
ReichNHölscherC. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: an in-depth review. Front Neurosci2022; 16: 970925.
50.
ZhangPMaoCSunA, et al.Real-world observations of GLP-1 receptor agonists and SGLT-2 inhibitors as potential treatments for Alzheimer’s disease. Alzheimers Dement2025; 21: e70639.
51.
CaoQTanC-CXuW, et al.The prevalence of dementia: a systematic review and meta-analysis. J Alzheimers Dis2020; 73: 1157–1166.
52.
MetelliSChaimaniA. Challenges in meta-analyses with observational studies. Evid Based Ment Health2020; 23: 83–87.
53.
FerrariFMorettiAVillaRF. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. Pharmacol Ther2022; 239: 108277.
54.
SimAYKimJYLeeY, et al.Neuroprotective roles of SGLT2 and DPP4 inhibitors: modulating ketone metabolism and suppressing NLRP3 inflammasome in T2D induced Alzheimer’s disease. Exp Neurol2025; 390: 115271.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
